Streetbeat News

NXGL

NEXGEL, Inc.

Industry

Medical - Instruments & Supplies

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

NexGel's stock price has declined following the announcement of their Q4 financial results, which fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 3:45 pm

NexGel (NASDAQ:NXGL) reported Q4 2023 GAAP EPS of $(0.20), missing the $(0.11) estimate, and sales of $1.082M, below the $1.380M estimate. Despite the miss, sales increased 106.49% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:24 pm

Numerous companies are scheduled to report their quarterly earnings on April 1, 2024, with a mix of projected profits and losses across various sectors. Notable mentions include Mach Natural Resources with expected earnings of $0.92 per share, Sigma Lithium with $0.18 per share, and PVH Corp with a significant $3.53 per share. Conversely, companies like Enservco and Nano X Imaging are anticipating losses. This diverse earnings landscape provides a broad view of the financial health across different industries.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 9:13 am

Earnings reports for March 28, 2024, include a mix of expected profits and losses across various sectors. Notable companies like Walgreens Boots Alliance and MSC Industrial Direct Co anticipate earnings, while others like Shimmick and Affimed project losses. The diversity of industries, from healthcare to technology and finance, highlights the varied performance within the market.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:24 am

NexGel (NASDAQ:NXGL) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.11. Investors are hopeful for a beat on this estimate and positive guidance for future growth. NexGel's stock performance has been strong, with shares up 102.21% over the last 52 weeks, trading at $2.7325 as of March 26.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

NEXGEL, Inc. (NASDAQ:NXGL) announced a registered direct offering of 462,090 shares and warrants for 231,040 shares at $2.11 per share, with warrants exercisable at $4.00. The offering, led by insiders including management and the Board, aims to raise approximately $975,000 before expenses. The funds are intended for additional working capital and to strengthen the balance sheet, following capital expenditures and strategic acquisitions in 2023. Alere Financial Partners, LLC served as the exclusive placement agent.

Portfolio Pulse from Happy Mohamed

February 21, 2024 | 9:46 pm

Nexgel (NXGL) has entered into a partnership with Stada Arzneimittel to distribute and commercialize over-the-counter (OTC) consumer health products in North America starting in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:07 pm

NEXGEL, Inc. has acquired Kenkoderm, a skincare line specializing in psoriasis treatment, with the aim of expanding its health and wellness consumer product portfolio. The acquisition is expected to be immediately accretive to NEXGEL's profitability, as Kenkoderm has been profitable over the trailing twelve months. NEXGEL plans to optimize marketing and supply chain operations to drive revenue growth and improve margins. Kenkoderm's products are sold primarily through e-commerce and Amazon, often as subscription bundles. NEXGEL's CEO, Adam Levy, intends to implement new marketing strategies and expand distribution channels, including retail. The transaction details can be found in NEXGEL's Form 8-K filed with the SEC on December 5, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 1:10 pm

NexGel (NASDAQ:NXGL) reported a narrower Q3 loss of $(0.10) per share compared to $(0.22) per share in the same quarter last year, showing a 54.55% improvement. Sales for the quarter increased by 114.96% to $1.22 million from $568.00 thousand in the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 13, 2023 | 9:32 pm

Numerous companies are scheduled to report their earnings on November 13, 2023, both before the bell and after. The list includes a wide range of industries and market caps, with some companies expected to report profits while others are anticipated to report losses. Key companies reporting include Tyson Foods, Henry Schein, and AECOM, with expected earnings per share of $0.29, $1.32, and $0.98 respectively. Other companies like IM Cannabis, Roivant Sciences, and Genius Sports are projected to report losses.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 11:40 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.